CD8A and type 1 diabetes mellitus: The efficacy of CD8 Treg expansion followed by inhibition of autoantibody generation and accompanying pathology can be tested in mouse models of autoimmune disease, including EAE, T1D (NOD) and SLE (BXSB-Yaa), or in various alloimmune models as shown above.